Healthcare provider profile · identity verified

Lily Sabouri, D.O.

Family Practice · ESSEXVILLE, MI · NPI 1952538613

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	432	124
Lisinopril	Lisinopril	382	117
Levothyroxine Sodium	Levothyroxine Sodium	380	96
Amlodipine Besylate	Amlodipine Besylate	307	97
Metformin Hcl	Metformin Hcl	245	66
Omeprazole	Omeprazole	234	74
Gabapentin	Gabapentin	224	62
Albuterol Sulfate Hfa	Albuterol Sulfate	206	64
Simvastatin	Simvastatin	192	51
Hydrochlorothiazide	Hydrochlorothiazide	189	55
Losartan Potassium	Losartan Potassium	155	46
Atenolol	Atenolol	133	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	132	28
Furosemide	Furosemide	114	33
Potassium Chloride	Potassium Chloride	114	32
Duloxetine Hcl	Duloxetine Hcl	112	31
Hydralazine Hcl	Hydralazine Hcl	111	35
Metoprolol Succinate	Metoprolol Succinate	106	30
Alendronate Sodium	Alendronate Sodium	104	26
Metoprolol Tartrate	Metoprolol Tartrate	99	31
Alprazolam	Alprazolam	98	20
Glipizide	Glipizide	98	30
Rosuvastatin Calcium	Rosuvastatin Calcium	92	28
Sertraline Hcl	Sertraline Hcl	91	28
Famotidine	Famotidine	90	26
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	90	24
Pantoprazole Sodium	Pantoprazole Sodium	89	31
Meloxicam	Meloxicam	88	26
Pravastatin Sodium	Pravastatin Sodium	88	30
Tramadol Hcl	Tramadol Hcl	86	14
Chlorthalidone	Chlorthalidone	79	25
Eliquis	Apixaban	76	22
Bupropion Hcl Sr	Bupropion Hcl	69	22
Ozempic	Semaglutide	67	14
Zolpidem Tartrate	Zolpidem Tartrate	66	suppressed
Clopidogrel	Clopidogrel Bisulfate	61	16
Tolterodine Tartrate	Tolterodine Tartrate	59	15
Citalopram Hbr	Citalopram Hydrobromide	58	20
Escitalopram Oxalate	Escitalopram Oxalate	58	17
Montelukast Sodium	Montelukast Sodium	58	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	14
Hydroxyzine Pamoate	Hydroxyzine Pamoate	56	20
Buspirone Hcl	Buspirone Hcl	52	22
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	51	14
Fluoxetine Hcl	Fluoxetine Hcl	49	17
Ibuprofen	Ibuprofen	49	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	47	25
Hydrocortisone	Hydrocortisone	47	18
Ventolin Hfa	Albuterol Sulfate	47	13
Fluticasone Propionate	Fluticasone Propionate	46	18
Tamsulosin Hcl	Tamsulosin Hcl	46	15
Azithromycin	Azithromycin	44	33
Carvedilol	Carvedilol	44	15
Prednisone	Prednisone	44	26
Pregabalin	Pregabalin	40	suppressed
Spironolactone	Spironolactone	40	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	12
Ropinirole Hcl	Ropinirole Hcl	35	suppressed
Trazodone Hcl	Trazodone Hcl	35	11
Fluconazole	Fluconazole	34	11
Warfarin Sodium	Warfarin Sodium	34	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	33	15
Allopurinol	Allopurinol	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Bupropion Xl	Bupropion Hcl	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	31	suppressed
Lorazepam	Lorazepam	31	suppressed
Humalog Kwikpen U-100	Insulin Lispro	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Acyclovir	Acyclovir	28	suppressed
Cephalexin	Cephalexin	28	23
Ondansetron Odt	Ondansetron	28	suppressed
Xarelto	Rivaroxaban	27	suppressed
Donepezil Hcl	Donepezil Hcl	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	22
Clonazepam	Clonazepam	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	20
Ondansetron Hcl	Ondansetron Hcl	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Sotalol	Sotalol Hcl	22	suppressed
Naproxen	Naproxen	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Glimepiride	Glimepiride	19	suppressed
Methylprednisolone	Methylprednisolone	19	13
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Estradiol	Estradiol	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Mounjaro	Tirzepatide	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Nystatin	Nystatin	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Maxalt Mlt	Rizatriptan Benzoate	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error